# A Clinical Evaluation of Baofeikang Granule in Combined Pulmonary Fibrosis and Emphysema Treatment

> **NCT02805699** · PHASE2 · UNKNOWN · sponsor: **Beijing Municipal Science & Technology Commission** · enrollment: 120 (estimated)

## Conditions studied

- Combined Pulmonary Fibrosis and Emphysema

## Interventions

- **DRUG:** Baofeikang Granule
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02805699
- **Lead sponsor:** Beijing Municipal Science & Technology Commission
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-06
- **Primary completion:** 2019-06
- **Final completion:** 2019-09
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2017-08-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02805699

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02805699, "A Clinical Evaluation of Baofeikang Granule in Combined Pulmonary Fibrosis and Emphysema Treatment". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02805699. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*